地中海-DASH干预神经退行性延迟饮食以改善轻度中风患者的认知功能:两项复制,试点随机对照试验的推理和设计
Qing Lin1, Hui Chen2, Jie Shen2
1Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, l167456q@163.com.
Cerebrovascular diseases (Basel, Switzerland)
|July 10, 2025
概括
在轻度中风幸存者中,MIND饮食可以改善认知功能. 这些试点试验将评估饮食.
科学领域:
- 神经科学和神经病学 神经科学和神经病学
- 营养科学 营养科学
- 公共卫生 公共卫生
背景情况:
- 脑卒中后认知障碍 (PSCI) 影响了三分之一的幸存者,预防选择有限.
- 为认知健康而设计的MIND饮食在轻度中风患者中尚未得到广泛研究.
- 在中风幸存者中MIND饮食效应的可重现性需要在不同的队列中进行调查.
研究的目的:
- 探索MIND饮食干预对轻度中风患者认知功能的影响.
- 在两个独立样本 (MINDICOMS和MINDICOMS II) 中评估MIND饮食干预效应的可重复性.
- 改进未来对饮食干预对中风后认知健康进行大规模试验的协议.
主要方法:
- 两项复制,试点,随机对照试验 (RCT) 涉及120名轻度中风患者 (35-70岁) 患有新发认知障碍.
- 被随机分配到26周的MIND饮食干预 (适应中国人口) 或对照组的参与者.
- 主要结果:全球认知功能的变化;次要结果:特定领域的认知,神经成像,生物标志物,饮食行为和日常生活.
主要成果:
- 将产生关于MIND饮食在改善轻度中风幸存者的认知功能的初步证据.
- 该研究将提供有关不同招聘波的干预效应可重现性的数据.
- 综合性结果测量将为潜在的生物学机制提供信息,这些机制是饮食对认知的影响的基础.
结论:
- MINDICOMS试验的目的是建立优化的饮食策略,以提高中风幸存者的认知能力.
- 研究结果将提供关于饮食与大脑相互作用的生物学机制的见解,以中风恢复为背景.
- 这项研究将为未来的大规模临床试验奠定基础,调查PSCI的饮食干预措施.
相关概念视频
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
213
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
213
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


